Liraglutide 3.0  mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit

CONCLUSION: We observed a high discontinuation rate in real-life clinical setting, where Liraglutide 3.0 therapy is paid out-of-pocket. While psychiatric symptoms might play a role in diminishing adherence to therapy, they do not prevent drug's effectiveness to promote weight loss. This finding underscores the potential advantages of liraglutide 3.0 mg therapy for individuals contending with obesity while simultaneously managing mental health challenges.LEVEL OF EVIDENCE: Level V, descriptive studies.PMID:38015342 | PMC:PMC10684642 | DOI:10.1007/s40519-023-01625-5
Source: Eating and weight disorders : EWD - Category: Eating Disorders & Weight Management Authors: Source Type: research